| Symbol | BCYC |
|---|---|
| Name | BICYCLE THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE, CB22 3AT, United Kingdom |
| Telephone | +44 1223261503 |
| Fax | — |
| — | |
| Website | https://www.bicycletherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. Additional info from NASDAQ: |
New Form DEF 14A - BICYCLE THERAPEUTICS PLC <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001104659-26-046806 <b>Size:</b> 4 MB
Read more(90% Positive) BICYCLE THERAPEUTICS PLC (BCYC) Provides Update on molecules for radiopharmaceutical use CAMBRIDGE
Read moreBicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Read moreHannay Michael Charles Ferguson 🔴 sold 1.8K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $5.05 Transaction Date: Apr 02, 2026 | Filing ID: 000004
Read moreThompson Travis Alvin 🔴 sold 901 shares of BICYCLE THERAPEUTICS PLC (BCYC) at $5.05 Transaction Date: Apr 02, 2026 | Filing ID: 000006
Read morePerry Jennifer Scott 🔴 sold 1.4K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $5.05 Transaction Date: Apr 02, 2026 | Filing ID: 000005
Read moreLee Kevin 🔴 sold 7.7K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $5.05 Transaction Date: Apr 02, 2026 | Filing ID: 000004
Read moreSkynner Michael 🔴 sold 2.4K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $5.05 Transaction Date: Apr 02, 2026 | Filing ID: 000004
Read more📋 Young Alethia (Officer) plans to sell 2K shares of BICYCLE THERAPEUTICS PLC (at $4.91 each, total $10K) Filed: Apr 02, 2026 | ID: 000134
Read more📋 Perry Jennifer Scott (Officer) plans to sell 2K shares of BICYCLE THERAPEUTICS PLC (at $4.91 each, total $7K) Filed: Apr 02, 2026 | ID: 000133
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | Phase1 | Advanced Solid Tumours | Completed | 2018-01-24 | 2023-11-20 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |